期刊文献+

越低越好,越快越好?——他汀类药物强化降脂利弊谈 被引量:3

下载PDF
导出
摘要 他汀类药物作为胆固醇合成途径的抑制剂,在降低血脂和心血管事件发生率方面有着非常重要的作用。循证医学研究发现他汀类强化降脂需要一个更加优化的质量控制标准,这个标准不应该是短期的将低密度脂蛋白胆固醇降得越低越好。相反一味的强化降脂将对病人带来副作用,这些副作用可能是致命的。
出处 《中国动脉硬化杂志》 CAS CSCD 2006年第9期737-740,共4页 Chinese Journal of Arteriosclerosis
  • 相关文献

参考文献12

  • 1Grundy SM,Cleeman JI,Bairey N,Brewer HB,Clark LT,Hunninghake DB,et al.Implications of recent clinical trials for the national cholesterol education program adult treatment panel Ⅲ guidelines[J].Circulation,2004,110:227-239
  • 2Brown MS,Goldstein JL.Lowering LDL-not only how low,but how long[J]? Science,2006,311 (5768):1 721-723
  • 3John C.Intensive lipid lowering with atorvastatin in patients with stable coronary disease[J].N Eng J Med,2005,352 (14):1 425-435
  • 4Cohen JC,Boerwinkle E,Mosley TH,Hobbs HH.Sequence variations in PCSK9,low LDL,and protection against coronary heart disease[J].N Engl J Med,2006,353:1 264-272
  • 5Larking PW.Cancer and low levels of plasma cholesterol:the relevance of cholesterol precursors and products to incidence of cancer[J].Prev Med,1999,29:383-390
  • 6Heart Protection Study Collaborative Group (HPSCG).MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals:a randomised placebo-controlled trial[J].Lancet,2002,360:7-22
  • 7Gotto AM.Evolving concepts of dyslipidemia,atherosclerosis,and cardiovascular disease the Louis F.Bishop Lecture[J].J Am Coll Cardiol,2005,46 (7):1 219-224
  • 8Gotto AM.Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the air force/texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS)[J].Circulation,2000,101:477-484
  • 9Stone PH.Effect of intensive lipid lowering,with or without antioxidant vitamins,compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease[J].Circulation,2005,111:1 747-755
  • 10LaRosa JC,Grundy SM,Waters DD,Shear C,Fruchart JC,Gotto AM,et al.Critical appraisal:intensive lipid lowering with atorvastatin in patients with stable coronary disease[J].N Engl J Med,2005,352:1 425-435

同被引文献20

  • 1王伟,王继文.Insig-SCAP-SREBP转运体系的研究进展[J].中国家禽,2005,27(z1):192-195. 被引量:1
  • 2Neil Kaplowitz.Hyperhomocysteinemia, endoplasmic reticulum stress, and alcoholic liver injury[J].World Journal of Gastroenterology,2004,10(12):1699-1708. 被引量:63
  • 3黄丹文,晏春根,朱东方,倪培华.SREBP-1C、GRP-94在小鼠肝细胞脂质代谢中的作用[J].基础医学与临床,2007,27(5):509-513. 被引量:2
  • 4Fahed AC,Nemer GM. Familial hypercholesterolemia:the lipids or the genes[J].Nutrition and Metabolism,2011.23.
  • 5迟家敏.实用血脂学[M]北京:人民卫生出版社,2010392-393.
  • 6Al-Allaf FA,Coutelle C,Waddington SN. LDLR-gene therapy for familial hypercholesterolaemia:problems,progress,and perspectives[J].Int Arch Med,2010.36.
  • 7Van Craeyveld E,Jacobs F,Gordts SC. Gene therapy for familial hypercholesterolemia[J].Current Pharmaceutical Design,2011,(24):2575-2591.
  • 8Kankkonen HM,V(a)h(a)kangas E,Marr RA. Longterm lowering of plasma cholesterol levels in LDL-receptordeficient WHHL rabbits by gene therapy[J].Molecular Therapy,2004,(04):548-556.
  • 9Lebherz C,Gao G,Louboutin JP. Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia[J].Journal of Gene Medicine,2004,(06):663-672.
  • 10Hibbitt OC,Harbottle RP,Waddington SN. Delivery and long-term expression of a 135 kb LDLR genomic DNA locus in vivo by hydrodynamic tail vein injection[J].Journal of Gene Medicine,2007,(06):488-497.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部